Hydrus Microstent: Definition, Uses, and Clinical Overview

Hydrus Microstent Introduction (What it is)

Hydrus Microstent is a tiny implant used in certain glaucoma surgeries.
It is designed to help lower eye pressure by improving fluid drainage inside the eye.
It is most commonly placed during cataract surgery in people who also have open-angle glaucoma.

Why Hydrus Microstent used (Purpose / benefits)

Hydrus Microstent is used to help manage glaucoma, a disease where damage to the optic nerve is often associated with elevated intraocular pressure (IOP), meaning pressure inside the eye. Lowering IOP is a central goal in glaucoma care because it is currently the main modifiable risk factor clinicians target to reduce the likelihood of further optic nerve damage over time.

Many people with glaucoma use prescription eye drops, laser procedures, or more traditional glaucoma surgeries to reduce IOP. Hydrus Microstent belongs to a category often referred to as minimally invasive glaucoma surgery (MIGS). In general terms, MIGS procedures aim to lower IOP with a more tissue-sparing approach than traditional filtering surgeries, though results and suitability vary by clinician and case.

Potential goals and benefits of Hydrus Microstent (in appropriate patients) may include:

• Lowering IOP by improving the eye’s natural drainage pathway.
• Reducing medication burden for some patients (for example, fewer drops), though many people still need glaucoma medication afterward.
• Combining glaucoma treatment with cataract surgery, so two issues can be addressed during one operative session when clinically appropriate.
• Aiming for a favorable safety profile compared with some more invasive glaucoma operations, while recognizing that every eye surgery carries risk.

Importantly, Hydrus Microstent is not a vision-correcting device like an intraocular lens implant for cataracts, and it does not restore optic nerve damage that has already occurred from glaucoma. Its purpose is pressure management, which may help slow future disease progression.

Indications (When ophthalmologists or optometrists use it)

Hydrus Microstent is typically considered in scenarios such as:

• Mild to moderate open-angle glaucoma where additional IOP lowering is desired.
• Open-angle glaucoma in a patient already planning cataract surgery, when a combined approach is appropriate.
• Patients using glaucoma eye drops who may benefit from a procedure aimed at lowering IOP and potentially reducing drop dependence (varies by clinician and case).
• Patients with ocular hypertension plus other risk factors, in selected situations where a glaucoma specialist judges an implant-based approach may be reasonable.
• People needing additional IOP control when medications and/or prior laser treatments have not achieved desired pressure targets (varies by clinician and case).

Contraindications / when it’s NOT ideal

Hydrus Microstent may be less suitable, or not suitable, in situations such as:

• Angle-closure glaucoma or narrow anterior chamber angles, where access to the drainage angle is limited or the mechanism of pressure elevation is different.
• Certain secondary glaucomas (for example, some inflammatory or neovascular causes), where the conventional drainage pathway may not function well.
• Active eye infection or significant uncontrolled inflammation, where implant placement could increase risk or worsen inflammation.
• Eyes with significant anatomic barriers to safe visualization or access to the drainage angle (for example, severe corneal opacity), depending on clinician assessment.
• Advanced glaucoma requiring very low target pressures, where other surgical approaches may be preferred because they can sometimes achieve lower IOP (varies by clinician and case).
• Known material sensitivity concerns relevant to implant composition (device-specific; varies by material and manufacturer).
• Situations where cataract surgery is not being performed, depending on regulatory indications, clinician preference, and individual risk–benefit considerations.

Only an eye surgeon can determine candidacy based on a full exam, glaucoma type, angle anatomy, optic nerve status, and treatment goals.

How it works (Mechanism / physiology)

Mechanism of action (high level)

Hydrus Microstent is designed to enhance outflow of aqueous humor, the clear fluid continuously produced inside the eye. In open-angle glaucoma, resistance to aqueous outflow—often at or near the trabecular meshwork and Schlemm’s canal—contributes to higher IOP.

At a high level, the device works by:

• Bypassing or reducing resistance at the trabecular meshwork at the point where fluid exits the anterior chamber.
• Scaffolding and dilating a portion of Schlemm’s canal, which is part of the eye’s conventional drainage pathway, to facilitate fluid movement into collector channels and then out of the eye.

Relevant eye anatomy (plain-language explanation)

• Anterior chamber: the fluid-filled space between the cornea (front clear window) and the iris (colored part).
• Trabecular meshwork: a spongy tissue at the drainage angle where aqueous humor exits.
• Schlemm’s canal: a circular channel that collects fluid leaving the trabecular meshwork and delivers it toward outflow channels.
• Collector channels: small pathways that move fluid from Schlemm’s canal into the eye’s venous system.

Hydrus Microstent is placed in the drainage angle so it can interact directly with this outflow system.

Onset, duration, and reversibility

• Onset: IOP effects, when they occur, are generally assessed in the early postoperative period and during ongoing follow-up; the timeline can vary by clinician and case.
• Duration: It is intended as a long-term implant. Long-term pressure control depends on healing response, disease severity, and other eye-specific factors.
• Reversibility: It is an implant rather than a temporary medication. In general, implants may be removable by a surgeon in select circumstances, but removal is not the usual plan and depends on anatomy and clinical context.

Hydrus Microstent Procedure overview (How it’s applied)

Hydrus Microstent is used as part of a surgical intervention performed by an ophthalmologist, commonly in conjunction with cataract surgery. The exact workflow varies, but a typical high-level sequence looks like this:

1. Evaluation / exam – Review of glaucoma history, IOP pattern, and current treatments. – Eye exam including optic nerve assessment and testing such as visual fields and imaging (as clinically relevant). – Examination of the drainage angle (often with gonioscopy) to understand anatomy and confirm open-angle status.

2. Preparation – Surgical planning, including discussion of goals (IOP lowering, medication reduction) and limitations. – Standard preoperative measurements and assessment of ocular health (cornea, lens/cataract status, retina, and overall eye anatomy). – Day-of-surgery preparation and anesthesia approach as determined by the surgical team.

3. Intervention – Cataract surgery is performed when the procedure is combined. – Using special visualization of the angle, the surgeon places the Hydrus Microstent through a small incision and positions it within Schlemm’s canal.

4. Immediate checks – The surgeon confirms device position and evaluates the eye for expected postoperative appearance. – IOP and anterior chamber status may be checked shortly after surgery.

5. Follow-up – Postoperative visits monitor healing, IOP, vision recovery after cataract surgery, and any need for ongoing or adjusted glaucoma therapy. – Some patients continue glaucoma drops; others may reduce or change medications depending on IOP response and clinician judgment.

This overview is intentionally general and does not replace clinician-specific procedural counseling.

Types / variations

Hydrus Microstent refers to a specific microstent design used for canal-based glaucoma surgery. Unlike broad categories such as “laser trabeculoplasty” (which has multiple laser types) or “contact lenses” (which have many materials), Hydrus Microstent itself is generally discussed as a single device platform rather than a family of many consumer-facing models.

Relevant “variations” are usually described in clinical context as:

• Standalone glaucoma procedure vs combined with cataract surgery

• In many settings it is most commonly used in combination with cataract surgery, though practice patterns and regulatory indications can vary by region.

• Placement strategy and intraoperative technique

• The intended target is the conventional outflow pathway, but the exact positioning and intraoperative decisions vary by surgeon and eye anatomy.

• Variation within the broader MIGS landscape (comparison class)

• Other MIGS options may target:
  • The trabecular meshwork/Schlemm’s canal (trabecular bypass or canal scaffolding devices)
  • The suprachoroidal space (less commonly used; availability varies)
  • The subconjunctival space (often more “filtering” in concept than canal-based MIGS)

When clinicians discuss “types,” they often mean these broader categories rather than multiple versions of Hydrus Microstent itself.

Pros and cons

Pros

• May lower intraocular pressure by enhancing the eye’s natural drainage pathway.
• Often performed at the same time as cataract surgery, limiting the need for separate operations in selected patients.
• Generally considered part of a tissue-sparing glaucoma surgery approach compared with traditional filtering surgeries (suitability varies by clinician and case).
• May reduce reliance on glaucoma eye drops for some patients, though results vary.
• Targets a well-studied anatomic route for aqueous outflow (trabecular meshwork and Schlemm’s canal).
• Does not involve creating an external drainage bleb in the way some glaucoma surgeries do (procedure-dependent).

Cons

• Not appropriate for all glaucoma types, especially when the angle is closed or the drainage pathway is severely compromised.
• IOP lowering may be insufficient for advanced disease needing very low target pressures (varies by clinician and case).
• As with any eye surgery, risks can include inflammation, bleeding, pressure spikes, or other complications; exact risks depend on individual factors and surgical context.
• Some patients will still need glaucoma drops or additional procedures afterward.
• Outcomes can be influenced by healing response and disease severity, which are not fully predictable.
• Implant positioning and angle anatomy can affect results and may occasionally require additional management.

Aftercare & longevity

Aftercare following Hydrus Microstent placement is typically tied closely to cataract surgery aftercare when the procedures are combined. The general goals of follow-up are to ensure the eye is healing well, monitor IOP trends, and assess whether glaucoma therapy (such as drops) needs to continue or be adjusted.

Factors that can influence outcomes and longevity include:

• Baseline glaucoma severity and target pressure needs

• People with more advanced glaucoma may require more IOP lowering than canal-based procedures can reliably provide, depending on the case.

• Angle anatomy and outflow system function

• The conventional drainage pathway must be sufficiently functional for canal-based approaches to work as intended.

• Healing response

• Postoperative healing can alter aqueous outflow. In general, scarring and inflammation responses vary between individuals.

• Adherence to follow-up

• Ongoing monitoring is central in glaucoma care because IOP and optic nerve stability need periodic reassessment over time.

• Other eye conditions

• Coexisting problems—such as uveitis (intraocular inflammation), significant corneal disease, or retinal disease—may affect postoperative course and overall visual function.

• Medication plan

• Some patients continue drops after surgery, while others may reduce medications. Decisions depend on IOP results, optic nerve status, and clinician judgment rather than a single universal timeline.

Hydrus Microstent is intended as a long-term implant, but long-term results are individualized and depend on both the device–eye interaction and the underlying glaucoma.

Alternatives / comparisons

Hydrus Microstent is one option within a broad glaucoma treatment spectrum. Alternatives are chosen based on glaucoma type, severity, anatomy, and treatment goals.

Common comparisons include:

• Observation/monitoring (selected cases)

• In ocular hypertension or very early glaucoma, clinicians sometimes monitor closely before escalating treatment, depending on overall risk profile.

• Prescription eye drops

• Drops reduce IOP by decreasing fluid production and/or increasing outflow. They are non-surgical but require consistent use and may cause side effects or adherence challenges.

• Laser trabeculoplasty (e.g., SLT)

• Selective laser trabeculoplasty is a common office-based procedure aimed at improving trabecular outflow. It does not involve an implant and may be repeated in some cases; duration of effect varies.

• Other canal-based MIGS procedures

• Other procedures may remove or incise trabecular tissue (trabeculotomy-type approaches) or use different micro-implants. Choice depends on anatomy, surgeon preference, and case goals.

• Subconjunctival MIGS or filtering procedures

• Some procedures create a new drainage pathway to a space under the conjunctiva (the clear membrane covering the white of the eye). These may achieve lower pressures in some patients but can involve different risk profiles and follow-up needs.

• Traditional glaucoma surgeries (trabeculectomy and tube shunts)

• These are often considered for more advanced glaucoma or when very low IOP is required. They can be effective but typically require more intensive postoperative management and carry different categories of complications.

In practice, glaucoma care is often stepwise, and patients may move between medications, laser, and surgery over time as the disease changes.

Hydrus Microstent Common questions (FAQ)

Q: Is Hydrus Microstent the same thing as cataract surgery?
No. Cataract surgery removes a cloudy natural lens and replaces it with an artificial intraocular lens. Hydrus Microstent is a separate glaucoma implant that may be placed during the same operation to help manage eye pressure.

Q: Does the Hydrus Microstent procedure hurt?
During surgery, anesthesia is used so patients generally do not feel pain in the typical way. Some scratchiness, mild discomfort, or light sensitivity can occur afterward, especially when combined with cataract surgery. Individual experience varies by clinician and case.

Q: Will Hydrus Microstent cure glaucoma?
Glaucoma is generally considered a chronic condition. Hydrus Microstent is designed to help lower IOP, which may reduce the risk of future optic nerve damage, but it does not reverse existing glaucoma damage. Long-term management and monitoring are still important.

Q: Can Hydrus Microstent help me stop using glaucoma drops?
Some patients are able to reduce the number of medications after surgery, while others still need drops. The outcome depends on factors like glaucoma severity, target pressure, and how the eye heals. Decisions about medications are individualized.

Q: How long do the results last?
Hydrus Microstent is intended as a permanent implant, but the durability of IOP lowering varies by person. Glaucoma can change over time, and additional treatments may be needed later. Long-term follow-up is used to track stability.

Q: Is Hydrus Microstent considered safe?
It is widely discussed within the MIGS category, which is designed to improve safety and recovery compared with some traditional glaucoma surgeries in appropriate patients. However, no eye surgery is risk-free, and complications can occur. Safety depends on individual anatomy, surgeon experience, and overall eye health.

Q: What is the recovery like after Hydrus Microstent?
Recovery is often similar to recovery after cataract surgery when the procedures are combined. Vision may fluctuate early, and follow-up visits are used to monitor healing and IOP. The exact timeline varies by clinician and case.

Q: When can someone drive or return to screen work after surgery?
Timing varies based on vision clarity, comfort, and the clinician’s assessment at follow-up. Screen use is often possible relatively soon for many people, but visual fluctuations can make it less comfortable at first. Driving should only resume when vision meets legal and safety requirements and the clinician confirms recovery is adequate.

Q: How much does Hydrus Microstent cost?
Costs vary widely by country, insurance coverage, surgical setting, and whether it is bundled with cataract surgery. Some patients have out-of-pocket expenses, while others may have coverage depending on policy rules and indications. The surgical practice or insurer typically provides the most accurate estimate.

Q: Can Hydrus Microstent be removed or replaced?
Because it is an implant, removal is not typically planned as part of routine care. In select circumstances, a surgeon may manage implant-related issues with additional procedures, which can include repositioning or other interventions depending on the situation. Whether removal is feasible varies by clinician and case.